150 related articles for article (PubMed ID: 1823174)
1. Clearance of liposomal gadolinium: in vivo decomplexation.
Unger EC; Fritz TA; Tilcock C; New TE
J Magn Reson Imaging; 1991; 1(6):689-93. PubMed ID: 1823174
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.
Tweedle MF; Wedeking P; Kumar K
Invest Radiol; 1995 Jun; 30(6):372-80. PubMed ID: 7490190
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution and clearance of liposomal gadolinium-DTPA.
Unger E; Cardenas D; Zerella A; Fajardo LL; Tilcock C
Invest Radiol; 1990 Jun; 25(6):638-44. PubMed ID: 2354925
[TBL] [Abstract][Full Text] [Related]
4. Gd-DOTA: characterization of a new paramagnetic complex.
Bousquet JC; Saini S; Stark DD; Hahn PF; Nigam M; Wittenberg J; Ferrucci JT
Radiology; 1988 Mar; 166(3):693-8. PubMed ID: 3340763
[TBL] [Abstract][Full Text] [Related]
5. Brain distribution of MRI contrast media in rats after intracisternal injection.
Allard M; Kien P; Caille JM; Bonnemain B; Simonnet G
J Neuroradiol; 1987; 14(4):383-7. PubMed ID: 3131496
[No Abstract] [Full Text] [Related]
6. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion.
Lancelot E
Invest Radiol; 2016 Nov; 51(11):691-700. PubMed ID: 27175546
[TBL] [Abstract][Full Text] [Related]
7. Gadolinium-labeled liposomes containing various amphiphilic Gd-DTPA derivatives: targeted MRI contrast enhancement agents for the liver.
Kabalka GW; Davis MA; Moss TH; Buonocore E; Hubner K; Holmberg E; Maruyama K; Huang L
Magn Reson Med; 1991 Jun; 19(2):406-15. PubMed ID: 1881329
[TBL] [Abstract][Full Text] [Related]
8. Mannan-coated liposome delivery of gadolinium-diethylenetriaminepentaacetic acid, a contrast agent for use in magnetic resonance imaging.
Kunimasa J; Inui K; Hori R; Kawamura Y; Endo K
Chem Pharm Bull (Tokyo); 1992 Sep; 40(9):2565-7. PubMed ID: 1446380
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
[TBL] [Abstract][Full Text] [Related]
10. Gadolinium cryptelates as MR contrast agents.
Knop RH; Frank JA; Dwyer AJ; Girton ME; Naegele M; Schrader M; Cobb J; Gansow O; Maegerstadt M; Brechbiel M
J Comput Assist Tomogr; 1987; 11(1):35-42. PubMed ID: 3805426
[TBL] [Abstract][Full Text] [Related]
11. Stability assessment of gadolinium complexes by P-31 and H-1 relaxometry.
Vander Elst L; Van Haverbeke Y; Goudemant JF; Muller RN
Magn Reson Med; 1994 Apr; 31(4):437-44. PubMed ID: 8208120
[TBL] [Abstract][Full Text] [Related]
12. Impact of Treatment With Chelating Agents Depends on the Stability of Administered GBCAs: A Comparative Study in Rats.
Boyken J; Frenzel T; Lohrke J; Jost G; Schütz G; Pietsch H
Invest Radiol; 2019 Feb; 54(2):76-82. PubMed ID: 30358694
[TBL] [Abstract][Full Text] [Related]
13. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media.
Puttagunta NR; Gibby WA; Puttagunta VL
Invest Radiol; 1996 Oct; 31(10):619-24. PubMed ID: 8889650
[TBL] [Abstract][Full Text] [Related]
14. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics.
Wedeking P; Kumar K; Tweedle MF
Magn Reson Imaging; 1992; 10(4):641-8. PubMed ID: 1501535
[TBL] [Abstract][Full Text] [Related]
15. The relaxivity of Gd-EOB-DTPA and Gd-DTPA in liver and kidney of the Wistar rat.
Shuter B; Tofts PS; Wang SC; Pope JM
Magn Reson Imaging; 1996; 14(3):243-53. PubMed ID: 8725190
[TBL] [Abstract][Full Text] [Related]
16. [Artificial contrasting during magnetic resonance tomography].
Sergeev PV; Panov OV; Egorova SV; Bolotova EN; Shimanovskii NL; Akhadov TA; Sviridov NK
Vestn Rentgenol Radiol; 1997; (1):45-52. PubMed ID: 9133071
[No Abstract] [Full Text] [Related]
17. An intravascular MRI contrast agent based on Gd(DO3A-Lys) for tumor angiography.
Yang CT; Chandrasekharan P; He T; Poh Z; Raju A; Chuang KH; Robins EG
Biomaterials; 2014 Jan; 35(1):327-36. PubMed ID: 24138829
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging.
Chong HS; Garmestani K; Bryant LH; Milenic DE; Overstreet T; Birch N; Le T; Brady ED; Brechbiel MW
J Med Chem; 2006 Mar; 49(6):2055-62. PubMed ID: 16539394
[TBL] [Abstract][Full Text] [Related]
19. The use of a binary chelate formulation: Could gadolinium based linear contrast agents be rescued by the addition of zinc selective chelates?
Gibby W; Parish W; Merrill RM; Fernandez D; Anderson CR; Merchel E; Parr R
Magn Reson Imaging; 2019 May; 58():76-81. PubMed ID: 30639754
[TBL] [Abstract][Full Text] [Related]
20. Quantification of dechelation of gadopentetate dimeglumine in rats.
Kasokat T; Urich K
Arzneimittelforschung; 1992 Jun; 42(6):869-76. PubMed ID: 1418049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
